CCM
AMRI

Cupps Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Cupps Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-257,840
Closed -$5.69M – 247
2014
Q3 		$5.69M Buy
+257,840
New +$5.28M 0.53% 75

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Cupps Capital Management's AMRI Position: Q4 2014 in Review

Cupps Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q4 2014, closing a stake of 257,840 shares — an estimated $5.69M sold.

Cupps Capital Management first reported a position in AMRI in Q3 2014 and held it in 1 quarter. The position peaked at $5.69M in Q3 2014. 132 funds tracked by Wall St. Rank hold AMRI as of Q4 2014.

  • Cupps Capital Management reported no remaining Albany Molecular Research Inc position as of Q4 2014 after selling out during the quarter.
  • Cupps Capital Management sold 257,840 Albany Molecular Research Inc shares in Q4 2014, an estimated $5.69M.
  • Cupps Capital Management first reported a position in Albany Molecular Research Inc in Q3 2014 and held it in 1 quarter.
  • Cupps Capital Management's Albany Molecular Research Inc position peaked at $5.69M in Q3 2014.
  • 132 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2014.

Based on Cupps Capital Management's 13F filing for Q4 2014, filed 9 Feb 2015.